MedPath

Effects of Vitamin D Supplementation on SOD,IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus (DM)

Not Applicable
Active, not recruiting
Conditions
Type2 Diabetes Mellitus
Interventions
Dietary Supplement: Vitamin D 5000 IU
Dietary Supplement: Placebo
Registration Number
NCT05596383
Lead Sponsor
Trisakti University
Brief Summary

The aim of this intervention clinical study are: evaluation the effect of vitamin D supplementation on anti-oxidant status, inflammation, insulin resistance in patients type 2 diabetes mellitus.

The research question is how the effect of vitamin D supplementation for 3 and 6 months on anti-oxidant status, inflammation and insulin resistance in patients type 2 diabetes mellitus.

The main tasks participants will be asked to do:

* interviews, filling the questionnaires, and giving informed consent after receiving an explanation by the researcher about the purpose of the research

* taking blood for screening examination which includes examination of Serum Glutamic Pyruvic Transaminase (SGPT), albumin, creatinine and blood Ca.

* participant who meet the inclusion and exclusion criteria, performed a physical examination (height and weight) and blood collection for examination 25(OH)D.

* Subjects/participant with vitamin D deficiency and insufficiency will be included in randomization, two groups: the group that received vitamin D3 5,000 IU and the group that received a placebo. Vitamin D 5000 IU and placebo taken daily for 6 months.

* Observations for 3 months and 6 months from the first time supplementation was given.

Treatments they'll be given:

* During the study, the subject's clinical condition will be monitored.

* Subject observations are monitored by telephone or google form to subject or their families

Detailed Description

Participant register: Patients type 2 DM aged \> 18 years who went to the Community Health Centers Mampang were interviewed, filled out questionnaires, and gave informed consent.Interview by interviewers with at least high school education after being given training first by researchers.

The data is entered in a computer excel table by the researcher. Accuracy, completeness of registration data using the screening form.

Data that contains detailed descriptions of each variable used by the registry:

* Gender: differences in the nature, form, and biological function of men and women that determine differences in reproduction, by interview using a questionnaire and identity card.

* Duration DM: time from the first time being diagnosed DM until the start of the study, expressed in months

* Subject's age: calculated from the time the study began with the date of birth listed on the identity card.

Standard Operating Procedures to address registry operations and analysis activities:

* patient recruitment : Patients type 2 DM aged \> 18 years who went to the Community Health Centers Mampang were interviewed.

* data collection: using screening form

* data management : using table excel computer

* data analysis : using Statistical Package for the Social Sciences (SPSS) versi 23

* report for adverse event: using form adverse event Sample size assessment : formula for hypothesis testing the mean difference of two groups Plan for missing data : back up data Statistical analysis plan to address the primary and secondary objectives: normality test (kolmogorov Smirnov), test statistic (T independent test or Mann Whitney test, Anova test)

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
112
Inclusion Criteria
  • male and female, aged > 18 years
  • period of DM ≤ 3 years
  • using a single anti-diabetic drug (monotherapy)
  • HbA1c > 6,5%
Exclusion Criteria
  • receive insulin therapy
  • kidney disease, liver disease
  • pregnant and lactating women
  • allergy history
  • hypercalcemia history
  • consumption of vitamin D in the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupVitamin D 5000 IUVitamin D, dosage form chewable tablet, dosage 5000 IU, frequency every day, duration six months
control groupPlaceboPlacebo (microcrystalline,calcium carbonate, sodium starch), dosage form chewable tablet, frequency every day, duration six month
Primary Outcome Measures
NameTimeMethod
level of Superoxide Dismutase (SOD)Change from Baseline at 3 and 6 months

SOD

Interleukin-6 (IL-6)Change from Baseline at 3 and 6 months

IL-6 in monocyte: % (method immunoflowcytometry);

pancreatic and duodenal homeobox 1(PDX-1) expressionChange from Baseline at 3 and 6 months

PDX-1 expression : ct (method polymerase chain reaction /PCR);

Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)Change from Baseline at 3 and 6 months

HOMA-IR : formula (fasting insulin (μIU/mL) x fasting blood glucose (mg/dL)/405

Secondary Outcome Measures
NameTimeMethod
vitamin D levelChange from Baseline at 3 and 6 months

Vitamin D: ng/mL;

(hemoglobin glycate) HbA1CChange from Baseline at 3 and 6 months

HbA1c: % ;

fasting blood glucoseChange from Baseline at 3 and 6 months

Fasting blood glucose: mg/dL ;

fasting insulinChange from Baseline at 3 and 6 months

Fasting insulin: μIU/mL

Trial Locations

Locations (1)

Community Health Centers Kecamatan Mampang Prapatan

🇮🇩

Jakarta, DKI Jakarta, Indonesia

© Copyright 2025. All Rights Reserved by MedPath